DEA

Health Law Alliance secured a full dismissal of all federal charges against NJ urologist Dr. Mukaram Gazi, marking an unprecedented acquittal in an otherwise unbroken string of 35 Insys-related prosecutions brought by federal and state prosecutors.

Understanding DEA registration requirements is crucial for healthcare providers handling controlled substances. Compliance with state and federal regulations helps avoid legal risks and ensures smooth practice operations.

Considering voluntarily surrendering your DEA registration? Our experts can help you navigate the process and understand your options. Call (800) 345-4125.

This article outlines the details of the three new telehealth rules promulgated by the Drug Enforcement Agency (DEA) and their impact on telehealth providers.

Learn how to obtain and protect your DEA registration with our step-by-step guide, updated for 2025 telehealth rules and audit trends—plus proven strategies to resolve denials and maintain compliance. Designed for healthcare providers by legal experts specializing in regulatory defense.

Learn what to expect during DEA inspections and how to protect your practice with proactive preparation strategies.

Discuss the DEA/HHS joint rule extending the prescribing flexibilities for controlled substances. Include: 1) an overview of the prescribing flexibilities that emerged during the COVID pandemic re: controlled substances; 2) the details of the proposed rule, and 3) what the rule means for providers.

DEA registration applications are receiving increased scrutiny as DEA turns its sights on providers and pharmacies to curtail controlled substance misuse and abuse. Applicants can and should take steps to ensure the registration process moves as quickly and smoothly as possible.

Texas pharmacies are facing increasing scrutiny by the Board of Pharmacy, which is working closely with the DEA and other federal agencies, to investigate regulatory violations and Medicaid claims.

HLA's Nancy Coffey, a former government official and healthcare expert, has been appointed to serve a three-year term as an independent pharmacy monitor for the Commonwealth of Massachusetts.